Ratings Aspen Pharmacare Holdings Limited

Equities

APN

ZAE000066692

End-of-day quote Johannesburg S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
220.7 ^ZAR	+1.98%		+1.70%	+8.46%

03-08	Aspen Pharmacare Holdings Limited Announces Board Changes	CI
03-05	Aspen Pharmacare Holdings Limited Seeks Acquisitions	CI

Summary

According to Refinitiv, the company's ESG score for its industry is good.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's high margin levels account for strong profits.
The company appears to be poorly valued given its net asset value.
Over the last twelve months, the sales forecast has been frequently revised upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B		B+
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.72%	43.34B		B-
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B		B+
SANDOZ GROUP AG	+10.31%	14.09B		-
CIPLA LIMITED	+12.07%	13.64B		B+
ZYDUS LIFESCIENCES LIMITED	+39.44%	11.43B		B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B		B+
THE MEDICINES COMPANY	-0.05%	6.79B	-	-
STADA ARZNEIMITTEL	-8.87%	5.73B	-	-
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-4.29%	4.71B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes